Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Can Iclusig Return To Market? Ariad Sees Path Through Restricted Distribution REMS

Executive Summary

Company reluctantly agrees to FDA’s request to suspend sales of ponatinib due to serious thrombotic risks while a narrower label and Risk Evaluation and Mitigation Strategy are negotiated. FDA cites serious adverse vascular event rates of 48% and 24% in Phase I and II ponatinib trials, respectively.


Related Content

With Iclusig’s Return, Ariad Gets A Second Chance To Get The Dose Right
FDA “Consumer Updates” To Get Advisory Committee Review
Iclusig Returns To Market With Smaller Patient Population, Stronger Warnings
Ariad Took Dismissive View Of CV Events In Iclusig Labeling Proposals
Iclusig Experience Reflects Regulatory Risk Inherent With Accelerated Approval
FDA’s Pazdur Highlights Need For Unbiased Toxicity Assessments
Ariad’s Leukemia Drug Iclusig Sails Through FDA In Less Than 3 Months
AstraZeneca VP Detlev Biniszkiewicz On Building An Oncology Strategy In China And Asia
FDA Re-Approves Tysabri, Recommends Second-Line Use
Tysabri Could Return In Fall; Marketing Suspended By Biogen Idec And Elan


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts